Fibronectin-Alginate microcapsules improve cell viability and protein secretion of encapsulated Factor IX-engineered human mesenchymal stromal cells

Bahareh Sayyar, Megan Dodd, Leah Marquez-Curtis, Anna Janowska-Wieczorek, Gonzalo Hortelano

    Research output: Contribution to journalArticle

    2 Citations (Scopus)

    Abstract

    Continuous delivery of proteins by engineered cells encapsulated in biocompatible polymeric microcapsules is of considerable therapeutic potential. However, this technology has not lived up to expectations due to inadequate cell - matrix interactions and subsequent cell death. In this study we hypothesize that the presence of fibronectin in an alginate matrix may enhance the viability and functionality of encapsulated human cord blood-derived mesenchymal stromal cells (MSCs) expressing the human Factor IX (FIX) gene. MSCs were encapsulated in alginate-PLL microcapsules containing 10, 100, or 500 μ g/ml fibronectin to ameliorate cell survival. MSCs in microcapsules with 100 and 500 μ g/ml fibronectin demonstrated improved cell viability and proliferation and higher FIX secretion compared to MSCs in non-supplemented microcapsules. In contrast, 10 μ g/ml fibronectin did not significantly affect the viability and protein secretion from the encapsulated cells. Differentiation studies demonstrated osteogenic (but not chondrogenic or adipogenic) differentiation capability and efficient FIX secretion of the enclosed MSCs in the fibronectin-alginate suspension culture. Thus, the use of recombinant MSCs encapsulated in fibronectin-alginate microcapsules in basal or osteogenic cultures may be of practical use in the treatment of hemophilia B.

    Original languageEnglish
    Pages (from-to)318-327
    Number of pages10
    JournalArtificial Cells, Nanomedicine and Biotechnology
    Volume43
    Issue number5
    DOIs
    Publication statusPublished - 2015

    Fingerprint

    Factor IX
    Alginate
    Mesenchymal Stromal Cells
    Fibronectins
    Capsules
    Cell Survival
    Cells
    Proteins
    Cell death
    Phase locked loops
    Human engineering
    Hemophilia B
    Blood
    Genes
    Fetal Blood
    Cell Communication
    alginic acid
    Suspensions
    Cell Death
    Cell Proliferation

    Keywords

    • Alginate
    • Bioactivity
    • Cell encapsulation
    • Factor IX
    • Fibronectin
    • Hemophilia B
    • Mesenchymal stromal cells

    ASJC Scopus subject areas

    • Biotechnology
    • Biomedical Engineering
    • Medicine (miscellaneous)
    • Pharmaceutical Science

    Cite this

    Fibronectin-Alginate microcapsules improve cell viability and protein secretion of encapsulated Factor IX-engineered human mesenchymal stromal cells. / Sayyar, Bahareh; Dodd, Megan; Marquez-Curtis, Leah; Janowska-Wieczorek, Anna; Hortelano, Gonzalo.

    In: Artificial Cells, Nanomedicine and Biotechnology, Vol. 43, No. 5, 2015, p. 318-327.

    Research output: Contribution to journalArticle

    @article{3fedabe10cf942ac9bfd62d3bc6fe415,
    title = "Fibronectin-Alginate microcapsules improve cell viability and protein secretion of encapsulated Factor IX-engineered human mesenchymal stromal cells",
    abstract = "Continuous delivery of proteins by engineered cells encapsulated in biocompatible polymeric microcapsules is of considerable therapeutic potential. However, this technology has not lived up to expectations due to inadequate cell - matrix interactions and subsequent cell death. In this study we hypothesize that the presence of fibronectin in an alginate matrix may enhance the viability and functionality of encapsulated human cord blood-derived mesenchymal stromal cells (MSCs) expressing the human Factor IX (FIX) gene. MSCs were encapsulated in alginate-PLL microcapsules containing 10, 100, or 500 μ g/ml fibronectin to ameliorate cell survival. MSCs in microcapsules with 100 and 500 μ g/ml fibronectin demonstrated improved cell viability and proliferation and higher FIX secretion compared to MSCs in non-supplemented microcapsules. In contrast, 10 μ g/ml fibronectin did not significantly affect the viability and protein secretion from the encapsulated cells. Differentiation studies demonstrated osteogenic (but not chondrogenic or adipogenic) differentiation capability and efficient FIX secretion of the enclosed MSCs in the fibronectin-alginate suspension culture. Thus, the use of recombinant MSCs encapsulated in fibronectin-alginate microcapsules in basal or osteogenic cultures may be of practical use in the treatment of hemophilia B.",
    keywords = "Alginate, Bioactivity, Cell encapsulation, Factor IX, Fibronectin, Hemophilia B, Mesenchymal stromal cells",
    author = "Bahareh Sayyar and Megan Dodd and Leah Marquez-Curtis and Anna Janowska-Wieczorek and Gonzalo Hortelano",
    year = "2015",
    doi = "10.3109/21691401.2014.885446",
    language = "English",
    volume = "43",
    pages = "318--327",
    journal = "Artificial Cells, Nanomedicine and Biotechnology",
    issn = "2169-1401",
    publisher = "Informa Healthcare",
    number = "5",

    }

    TY - JOUR

    T1 - Fibronectin-Alginate microcapsules improve cell viability and protein secretion of encapsulated Factor IX-engineered human mesenchymal stromal cells

    AU - Sayyar, Bahareh

    AU - Dodd, Megan

    AU - Marquez-Curtis, Leah

    AU - Janowska-Wieczorek, Anna

    AU - Hortelano, Gonzalo

    PY - 2015

    Y1 - 2015

    N2 - Continuous delivery of proteins by engineered cells encapsulated in biocompatible polymeric microcapsules is of considerable therapeutic potential. However, this technology has not lived up to expectations due to inadequate cell - matrix interactions and subsequent cell death. In this study we hypothesize that the presence of fibronectin in an alginate matrix may enhance the viability and functionality of encapsulated human cord blood-derived mesenchymal stromal cells (MSCs) expressing the human Factor IX (FIX) gene. MSCs were encapsulated in alginate-PLL microcapsules containing 10, 100, or 500 μ g/ml fibronectin to ameliorate cell survival. MSCs in microcapsules with 100 and 500 μ g/ml fibronectin demonstrated improved cell viability and proliferation and higher FIX secretion compared to MSCs in non-supplemented microcapsules. In contrast, 10 μ g/ml fibronectin did not significantly affect the viability and protein secretion from the encapsulated cells. Differentiation studies demonstrated osteogenic (but not chondrogenic or adipogenic) differentiation capability and efficient FIX secretion of the enclosed MSCs in the fibronectin-alginate suspension culture. Thus, the use of recombinant MSCs encapsulated in fibronectin-alginate microcapsules in basal or osteogenic cultures may be of practical use in the treatment of hemophilia B.

    AB - Continuous delivery of proteins by engineered cells encapsulated in biocompatible polymeric microcapsules is of considerable therapeutic potential. However, this technology has not lived up to expectations due to inadequate cell - matrix interactions and subsequent cell death. In this study we hypothesize that the presence of fibronectin in an alginate matrix may enhance the viability and functionality of encapsulated human cord blood-derived mesenchymal stromal cells (MSCs) expressing the human Factor IX (FIX) gene. MSCs were encapsulated in alginate-PLL microcapsules containing 10, 100, or 500 μ g/ml fibronectin to ameliorate cell survival. MSCs in microcapsules with 100 and 500 μ g/ml fibronectin demonstrated improved cell viability and proliferation and higher FIX secretion compared to MSCs in non-supplemented microcapsules. In contrast, 10 μ g/ml fibronectin did not significantly affect the viability and protein secretion from the encapsulated cells. Differentiation studies demonstrated osteogenic (but not chondrogenic or adipogenic) differentiation capability and efficient FIX secretion of the enclosed MSCs in the fibronectin-alginate suspension culture. Thus, the use of recombinant MSCs encapsulated in fibronectin-alginate microcapsules in basal or osteogenic cultures may be of practical use in the treatment of hemophilia B.

    KW - Alginate

    KW - Bioactivity

    KW - Cell encapsulation

    KW - Factor IX

    KW - Fibronectin

    KW - Hemophilia B

    KW - Mesenchymal stromal cells

    UR - http://www.scopus.com/inward/record.url?scp=84946402797&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84946402797&partnerID=8YFLogxK

    U2 - 10.3109/21691401.2014.885446

    DO - 10.3109/21691401.2014.885446

    M3 - Article

    VL - 43

    SP - 318

    EP - 327

    JO - Artificial Cells, Nanomedicine and Biotechnology

    JF - Artificial Cells, Nanomedicine and Biotechnology

    SN - 2169-1401

    IS - 5

    ER -